IRLAB Therapeutics AB
STO:IRLAB A

Watchlist Manager
IRLAB Therapeutics AB Logo
IRLAB Therapeutics AB
STO:IRLAB A
Watchlist
Price: 12.6 SEK -1.95% Market Closed
Market Cap: 652.5m SEK
Have any thoughts about
IRLAB Therapeutics AB?
Write Note

Net Margin
IRLAB Therapeutics AB

-287.3%
Current
-624%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-287.3%
=
Net Income
-119.5m
/
Revenue
41.6m

Net Margin Across Competitors

Country SE
Market Cap 653.5m SEK
Net Margin
-287%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 788.1B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 3.4T DKK
Net Margin
35%
Country US
Market Cap 384.8B USD
Net Margin
17%
Country US
Market Cap 259.4B USD
Net Margin
22%
Country CH
Market Cap 213.6B CHF
Net Margin
20%
Country UK
Market Cap 171.2B GBP
Net Margin
13%
Country CH
Market Cap 183.5B CHF
Net Margin
33%
Country US
Market Cap 160.4B USD
Net Margin
7%

Profitability Report

View the profitability report to see the full profitability analysis for IRLAB Therapeutics AB.

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-287.3%
=
Net Income
-119.5m
/
Revenue
41.6m
What is the Net Margin of IRLAB Therapeutics AB?

Based on IRLAB Therapeutics AB's most recent financial statements, the company has Net Margin of -287.3%.